Literature DB >> 26247684

A comparison of glycated albumin and glycosylated hemoglobin for the screening of diabetes mellitus in Taiwan.

Powen Hsu1, Masumi Ai2, Eiichiro Kanda3, Neng-Chun Yu4, Hsiao-Lien Chen5, Huan-Wen Chen5, Ming-Hui Cheng6, Takuji Kohzuma7, Ernst J Schaefer8, Masayuki Yoshida9.   

Abstract

OBJECTIVE: Glycated albumin (GA) values reflect an average plasma glucose level over approximately 2-4 weeks, and the assay is stable and can be run on serum or plasma. The aim of this study was to determine the universality and the clinical utility of GA in screening for diabetes mellitus.
METHODS: Subjects consisted of 2192 male and female residents in Yi-lan County, Northern Taiwan (mean age 60.1 years), of whom 54.2% (n = 1188) had previously been diagnosed and treated for diabetes. Fasting blood samples were obtained to measure HbA1c, plasma glucose, serum GA, insulin, and measures of kidney and liver function. The reference values for these parameters were determined. Data from patients with diabetes and non-diabetic controls were also compared.
RESULTS: Mean GA values were 13.8% in controls and 18.1% in diabetic subjects (31.2% higher, p < 0.0001), while mean HbA1c values were 5.6% in controls and 7.2% in diabetic subjects (29.2% higher, p < 0.0001). The 95th percentile values for GA and HbA1c in controls were 16.1% and 6.2%, respectively. Our suggested GA and HbA1c cut-points for prediabetes at the 75th percentile of the normal population would be 14.6% and 5.8%, respectively. For both parameters, values greater than these cut-points provided a reasonable degree of specificity and sensitivity for risk of having diabetes, while a GA value of 16.5% corresponds to an HbA1c level of 6.5%, diagnostic of diabetes.
CONCLUSION: These data indicate that GA values can be used as a surrogate parameter for HbA1c in screening for prediabetes and diabetes mellitus.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Glucose lowering medication; Glycated albumin; Glycosylated hemoglobin; Prevention; Reference range; Taiwan

Mesh:

Substances:

Year:  2015        PMID: 26247684     DOI: 10.1016/j.atherosclerosis.2015.07.037

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  11 in total

Review 1.  Pediatric Clinical Endpoint and Pharmacodynamic Biomarkers: Limitations and Opportunities.

Authors:  Jean C Dinh; Chelsea M Hosey-Cojocari; Bridgette L Jones
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

2.  Combining HbA1c and glycated albumin improves detection of dysglycaemia in mixed-ancestry South Africans.

Authors:  Andre Pascal Kengne; Tandi E Matsha; David B Sacks; Annalise E Zemlin; Rajiv T Erasmus; Anne E Sumner
Journal:  EClinicalMedicine       Date:  2022-05-23

Review 3.  A Systematic Review of Body Fluids Biomarkers Associated With Early Neurological Deterioration Following Acute Ischemic Stroke.

Authors:  Xiaotan Ji; Long Tian; Shumei Yao; Fengyue Han; Shenna Niu; Chuanqiang Qu
Journal:  Front Aging Neurosci       Date:  2022-05-30       Impact factor: 5.702

4.  Improved Detection of Abnormal Glucose Tolerance in Africans: The Value of Combining Hemoglobin A1c With Glycated Albumin.

Authors:  Arsene F Hobabagabo; Nana H Osei-Tutu; Thomas Hormenu; Elyssa M Shoup; Christopher W DuBose; Lilian S Mabundo; Joon Ha; Arthur Sherman; Stephanie T Chung; David B Sacks; Anne E Sumner
Journal:  Diabetes Care       Date:  2020-08-14       Impact factor: 19.112

5.  Factors associated with glycated albumin in adults without diabetes.

Authors:  Priscila Aparecida Corrêa Freitas; Mayana Kieling Hernandez; Joíza Lins Camargo
Journal:  Med Pharm Rep       Date:  2021-04-29

6.  Lipoprotein Subfractions and Glucose Homeostasis in Prediabetes and Diabetes in Taiwan.

Authors:  Hung Hsu; Powen Hsu; Ming-Hui Cheng; Yasuki Ito; Eiichiro Kanda; Ernst J Schaefer; Masumi Ai
Journal:  J Atheroscler Thromb       Date:  2019-02-07       Impact factor: 4.928

7.  Glycated Albumin for Glycemic Control in T2DM Population: A Multi-Dimensional Evaluation.

Authors:  Lucrezia Ferrario; Fabrizio Schettini; Angelo Avogaro; Chiara Bellia; Federico Bertuzzi; Graziella Bonetti; Antonio Ceriello; Marcello Ciaccio; Massimiliano Corsi Romanelli; Elena Dozio; Luca Falqui; Angela Girelli; Antonio Nicolucci; Gianluca Perseghin; Mario Plebani; Umberto Valentini; Martina Zaninotto; Silvana Castaldi; Emanuela Foglia
Journal:  Clinicoecon Outcomes Res       Date:  2021-05-27

8.  Effects of different anticoagulants on glycated albumin quantification.

Authors:  Graziella Bonetti; Nicola Di Gaetano; Renata Paleari; Ferruccio Ceriotti
Journal:  Biochem Med (Zagreb)       Date:  2018-12-15       Impact factor: 2.313

9.  Glycated albumin as a diagnostic tool in diabetes: An alternative or an additional test?

Authors:  Fernando Chimela Chume; Mayana Hernandez Kieling; Priscila Aparecida Correa Freitas; Gabriela Cavagnolli; Joíza Lins Camargo
Journal:  PLoS One       Date:  2019-12-31       Impact factor: 3.240

10.  Glycated Albumin, a Novel Biomarker for Short-Term Functional Outcomes in Acute Ischemic Stroke.

Authors:  Yerim Kim; Sang-Hwa Lee; Min Kyoung Kang; Tae Jung Kim; Han-Yeong Jeong; Eung-Joon Lee; Jeonghoon Bae; Kipyoung Jeon; Ki-Woong Nam; Byung-Woo Yoon
Journal:  Brain Sci       Date:  2021-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.